OTC Medicines

Browse OTC Medicines Content

Industry appreciates this guidance to enable the assembly of suitable and successful OMORs. FDA must adopt standards and expectations consistent with the intent of OMUFA, rather than the NDA paradigm, with which it is very familiar.

Jun 12, 2023

CHPA appreciates this opportunity to comment on the Synthetic Dye Petition submitted to the California Department of Public Health requesting that a warning be placed on food and dietary supplement products related to adverse neurobehavioral effects purportedly associated with ingestion of synthetic food dyes.

May 12, 2023

CHPA today released the below statement following a U.S. Food and Drug Administration (FDA) joint advisory committee meeting, which concluded that Opill®, a once-daily oral contraceptive, should be approved as the first oral contraceptive for use without a prescription:  

May 10, 2023

Ellen Guritzky and Anousheh Alavi from Haleon, with CHPA's Anita Brikman, discuss the importance of preserving gum health to avoid tooth loss. Catch the full conversation on this episode of CHPA Chat.

May 8, 2023

The Consumer Healthcare Products Association (CHPA) today released the below statement following the U.S. Food and Drug Administration’s (FDA) public release of briefing materials

May 5, 2023

Millions of Americans rely on OTC medicines. Following the COVID-19 pandemic, OTCs have become an even more essential part of the treatment toolbox. Today, we take a look at the value created by OTC medicines as we walk through some of the top findings from CHPA's latest OTC value study.

Apr 10, 2023

Filter Results